This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Are Options Traders Betting on a Big Move in Avalo Therapeutics (AVTX) Stock?
by Zacks Equity Research
Investors need to pay close attention to Avalo Therapeutics (AVTX) stock based on the movements in the options market lately.
Wall Street Analysts Predict a 191% Upside in Avalo Therapeutics, Inc. (AVTX): Here's What You Should Know
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 191.3% in Avalo Therapeutics, Inc. (AVTX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Wall Street Analysts Predict a 230% Upside in Avalo Therapeutics, Inc. (AVTX): Here's What You Should Know
by Zacks Equity Research
The consensus price target hints at a 230.1% upside potential for Avalo Therapeutics, Inc. (AVTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Is Artelo Biosciences, Inc. (ARTL) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Artelo Biosciences, Inc. (ARTL) and Avalo Therapeutics, Inc. (AVTX) have performed compared to their sector so far this year.
Do Options Traders Know Something About Avalo (AVTX) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Avalo (AVTX) stock based on the movements in the options market lately.